iRhythm (IRTC) Q2 Revenue Jumps 26%
iRhythm Technologies (NASDAQ:IRTC), a medical device company specializing in cardiac monitoring technology, reported its Q2 FY2025 results on July 31, 2025. The highlight was record revenue (GAAP) of $186.7 million, up 26.1% from the previous year and beating analyst expectations by $12.7 million. The company also delivered a Non-GAAP loss per share of $0.32, much better than the anticipated $0.49 loss. Gross margin rose to 71.2%, demonstrating operational improvements. Overall, the quarter showcased robust growth and margin progress, though net losses remain an ongoing concern as iRhythm continues to scale its technology-driven healthcare business.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2024 earnings report.
iRhythm Technologies is best known for its Zio platform, which combines wearable electrocardiogram (ECG) sensors and a cloud-based analytics system to detect cardiac arrhythmias. These devices generate long-term heart rhythm data, offering higher diagnostic accuracy than traditional monitoring methods. The Zio family includes the Zio Monitor long-term patch, the Zio XT, and the Zio AT, a mobile cardiac telemetry (MCT) solution for patients needing real-time analysis.
Source Fool.com
